|
31.05.2021 22:53:00
|
Advisory - Multiple lots of irbesartan, losartan and valsartan drugs recalled due to azido impurity
OTTAWA, ON, May 30, 2021 /CNW/ -
Summary
- Products: Irbesartan, losartan and valsartan drugs
- Issue: Several companies are recalling multiple lots of these products due to the presence of an azido impurity
- What to do: Continue taking your medication unless you have been advised to stop by your healthcare provider. Not treating your condition may pose a greater health risk.
Issue
Health Canada is informing Canadians that several companies are recalling multiple lots of irbesartan, losartan and valsartan drug products after tests found an azido impurity above the acceptable limit (see list of affected products below).
Irbesartan, losartan and valsartan are all prescription angiotensin receptor blocker (ARB) drugs, which are also known as "sartans." Sartans are a class of drugs used to treat patients with high blood pressure to help prevent heart attacks and stroke. They are also used in patients with heart failure or those who have had a recent heart attack.
The azido impurity, (5-(4'-(azidomethyl)-[1,1'-biphenyl]-2yl)-1H-tetrazole, is considered a mutagen. A mutagen is a chemical substance that can cause a change in the DNA of a cell. These mutations may increase the risk of cancer but the specific risk for this azido impurity to cause cancer in humans is unknown.
There are established international guidelines that recommend that mutagenic impurities be kept at or below a specific level because exposure to a mutagen over the long term at a level above what is considered to be safe, has the potential to increase the risk of cancer. A person taking a drug daily for 70 years that contains this azido impurity at or below the acceptable level is not expected to have an increased risk of cancer.
Not all lots of irbesartan, losartan and valsartan from these companies are affected by this issue; however, it is possible that the recalls may affect the supply of some products. Patients should speak with their doctor or pharmacist to discuss alternatives should their regular prescribed drug not be available.
The Department expects manufacturers to take any necessary actions to reduce or eliminate the azido impurity. Impacted companies have been directed to implement control measures to ensure that the level of the impurity in their products are at or below the acceptable level. Health Canada is monitoring the effectiveness of the recalls. Should additional recalls be deemed necessary, Health Canada will inform Canadians.
What you should do
- Continue taking your medication unless you have been advised to stop by your healthcare provider. There is no immediate risk to patients taking these medications, since the potential increased risk of cancer is with long-term exposure to the impurity. Not treating your condition may pose a greater health risk.
- If you have been using an affected product, contact your healthcare provider as soon as possible to discuss treatment options. Pharmacists may be able to provide a product not affected by the recall, or your doctor may prescribe a different medication for your condition.
- Report any health product side effects or complaints to Health Canada.
- Contact the company directly if you have questions about a recall:
- Auro Pharma Inc. by calling toll free at 1-855-568-2511, or by email at cs@auropharma.ca
- Mint Pharmaceuticals Inc. by calling 1-905-795-9437, extension 2201, or by email at orders@mintpharmaceuticals.com
- Pharmascience Inc. by calling toll free at 1-800-340-9735
- Pro Doc Ltd. by calling toll free at 1-800-361-8559
- Sandoz Canada Inc. by calling toll free at 1-800-343-8839
- Sanis Health Inc. by calling toll free at 1-866-236-4076, or by email at quality@sanis.com
- Sivem Pharmaceuticals ULC by calling toll free at 1-855-757-4836
- Sun Pharma Canada Inc. by calling toll free at 1-800-268-1975, or by email at customerservice@taro.ca
- Teva Canada Ltd. by calling toll free at 1-800-268-412
Affected products
Products are listed alphabetically by name.
Product | Company | DIN | Lot | Expiry |
Irbesartan | ||||
IRBESARTAN 150 mg TABLETS | Pro Doc Ltd. | 02365200 | 617491 | July 2021 |
IRBESARTAN 150 mg TABLETS | Pro Doc Ltd. | 02365200 | 618112 | March 2022 |
IRBESARTAN 150 mg TABLETS | Pro Doc Ltd. | 02365200 | 624632 | January 2023 |
IRBESARTAN 150 mg TABLETS | Pro Doc Ltd. | 02365200 | 624633 | January 2023 |
IRBESARTAN 150 mg TABLETS | Pro Doc Ltd. | 02365200 | 630546 | May 2023 |
IRBESARTAN 300 mg TABLETS | Pro Doc Ltd. | 02365219 | 615929 | June 2021 |
IRBESARTAN 300 mg TABLETS | Pro Doc Ltd. | 02365219 | 617091 | June 2021 |
IRBESARTAN 300 mg TABLETS | Pro Doc Ltd. | 02365219 | 617264 | June 2021 |
IRBESARTAN 300 mg TABLETS | Pro Doc Ltd. | 02365219 | 620694 | March 2022 |
IRBESARTAN 300 mg TABLETS | Pro Doc Ltd. | 02365219 | 624189 | May 2022 |
IRBESARTAN 300 mg TABLETS | Pro Doc Ltd. | 02365219 | 624190 | May 2022 |
IRBESARTAN 300 mg TABLETS | Pro Doc Ltd. | 02365219 | 624191 | January 2023 |
IRBESARTAN 300 mg TABLETS | Pro Doc Ltd. | 02365219 | 624192 | January 2023 |
IRBESARTAN 75 mg TABLETS | Pro Doc Ltd. | 02365197 | 616518 | June 2021 |
IRBESARTAN 75 mg TABLETS | Pro Doc Ltd. | 02365197 | 619960 | November 2021 |
IRBESARTAN 75 mg TABLETS | Pro Doc Ltd. | 02365197 | 622192 | May 2022 |
IRBESARTAN 75 mg TABLETS | Pro Doc Ltd. | 02365197 | 622193 | December 2022 |
IRBESARTAN HCT/TABLET/150/12.5 mg | Sivem Pharmaceuticals ULC | 02385317 | JN5054 | January 2022 |
IRBESARTAN HCT/TABLET/150/12.5 mg | Sivem Pharmaceuticals ULC | 02385317 | JV2163 | April 2022 |
IRBESARTAN HCT/TABLET/150/12.5 mg | Sivem Pharmaceuticals ULC | 02385317 | JY7867 | June 2022 |
IRBESARTAN HCT/TABLET/150/12.5 mg | Sivem Pharmaceuticals ULC | 02385317 | KT2519 | May 2023 |
IRBESARTAN HCT/TABLET/150/12.5 mg | Sivem Pharmaceuticals ULC | 02385317 | KT2520 | May 2023 |
IRBESARTAN HCT/TABLET/300/12.5 mg | Sivem Pharmaceuticals ULC | 02385325 | JP2979 | January 2022 |
IRBESARTAN HCT/TABLET/300/12.5 mg | Sivem Pharmaceuticals ULC | 02385325 | JP2980 | January 2022 |
IRBESARTAN HCT/TABLET/300/12.5 mg | Sivem Pharmaceuticals ULC | 02385325 | JU8206 | April 2022 |
IRBESARTAN HCT/TABLET/300/12.5 mg | Sivem Pharmaceuticals ULC | 02385325 | JU8207 | April 2022 |
IRBESARTAN HCT/TABLET/300/25 mg | Sivem Pharmaceuticals ULC | 02385333 | JX8881 | June 2022 |
IRBESARTAN HCT/TABLET/300/25 mg | Sivem Pharmaceuticals ULC | 02385333 | JX8882 | June 2022 |
IRBESARTAN HCT/TABLET/300/25 mg | Sivem Pharmaceuticals ULC | 02385333 | JB0216 | May 2021 |
IRBESARTAN/TABLET/150 mg | Sivem Pharmaceuticals ULC | 02385295 | KC7215 | July 2021 |
IRBESARTAN/TABLET/300 mg | Sivem Pharmaceuticals ULC | 02385309 | KF8325 | July 2021 |
IRBESARTAN-HCTZ 150/12.5 mg TABLETS | Pro Doc Ltd. | 02365162 | JN4976 | January 2022 |
IRBESARTAN-HCTZ 150/12.5 mg TABLETS | Pro Doc Ltd. | 02365162 | JU3231 | January 2022 |
IRBESARTAN-HCTZ 150/12.5 mg TABLETS | Pro Doc Ltd. | 02365162 | JY1913 | June 2022 |
IRBESARTAN-HCTZ 300/12.5 mg TABLETS | Pro Doc Ltd. | 02365170 | HW0586 | February 2021 |
IRBESARTAN-HCTZ 300/12.5 mg TABLETS | Pro Doc Ltd. | 02365170 | HW0587 | February 2021 |
IRBESARTAN-HCTZ 300/12.5 mg TABLETS | Pro Doc Ltd. | 02365170 | JR7823 | February 2022 |
IRBESARTAN-HCTZ 300/12.5 mg TABLETS | Pro Doc Ltd. | 02365170 | JR7824 | February 2022 |
IRBESARTAN-HCTZ 300/12.5 mg TABLETS | Pro Doc Ltd. | 02365170 | JU7506 | April 2022 |
IRBESARTAN-HCTZ 300/25 mg TABLETS | Pro Doc Ltd. | 02365189 | JS0731 | February 2022 |
MINT- IRBESARTAN /HCTZ 150/12.5 mg TABLETS | Mint Pharmaceuticals Inc. | 02392992 | 1805011398 | August 2021 |
MINT- IRBESARTAN /HCTZ 300/12.5 mg TABLETS | Mint Pharmaceuticals Inc. | 02393018 | 1805011402 | August 2021 |
MINT- IRBESARTAN /HCTZ 300/25.0 mg TABLETS | Mint Pharmaceuticals Inc. | 02393026 | 1805011576 | August 2021 |
pms-IRBESARTAN 150 mg TABLETS | Pharmascience Inc. | 02317079 | 617492 | July 2021 |
pms-IRBESARTAN 150 mg TABLETS | Pharmascience Inc. | 02317079 | 624634 | January 2023 |
pms-IRBESARTAN 150 mg TABLETS | Pharmascience Inc. | 02317079 | 630661 | May 2023 |
pms-IRBESARTAN 75 mg TABLETS | Pharmascience Inc. | 02317060 | 617466 | November 2021 |
pms-IRBESARTAN 75 mg TABLETS | Pharmascience Inc. | 02317060 | 617467 | November 2021 |
pms-IRBESARTAN 75 mg TABLETS | Pharmascience Inc. | 02317060 | 617468 | November 2021 |
pms-IRBESARTAN 75 mg TABLETS | Pharmascience Inc. | 02317060 | 620272 | November 2021 |
pms-IRBESARTAN 75 mg TABLETS | Pharmascience Inc. | 02317060 | 622195 | December 2022 |
pms-IRBESARTAN 75 mg TABLETS | Pharmascience Inc. | 02317060 | 624738 | December 2022 |
pms-IRBESARTAN-HCTZ 300/12.5 mg TABLETS | Pharmascience Inc. | 02328526 | 621822 | July 2021 |
pms-IRBESARTAN-HCTZ 300/12.5 mg TABLETS | Pharmascience Inc. | 02328526 | 621823 | November 2021 |
pms-IRBESARTAN-HCTZ 300/12.5 mg TABLETS | Pharmascience Inc. | 02328526 | 625318 | February 2022 |
pms-IRBESARTAN-HCTZ 300/12.5 mg TABLETS | Pharmascience Inc. | 02328526 | 625902 | January 2022 |
pms-IRBESARTAN-HCTZ 300/12.5 mg TABLETS | Pharmascience Inc. | 02328526 | 629920 | July 2022 |
pms-IRBESARTAN-HCTZ 300/12.5 mg TABLETS | Pharmascience Inc. | 02328526 | 631052 | October 2022 |
pms-IRBESARTAN-HCTZ 300/12.5 mg TABLETS | Pharmascience Inc. | 02328526 | 632583 | November 2022 |
pms-IRBESARTAN-HCTZ 300/25 mg TABLETS | Pharmascience Inc. | 02328534 | 624235 | June 2021 |
RAN- IRBESARTAN Tablets 150 mg | Sun Pharma Canada Inc. | 02406829 | AB47146 | April 2023 |
RAN- IRBESARTAN Tablets 150 mg | Sun Pharma Canada Inc. | 02406829 | AB47147 | April 2023 |
RAN- IRBESARTAN Tablets 150 mg | Sun Pharma Canada Inc. | 02406829 | AB47148 | April 2023 |
RAN- IRBESARTAN Tablets 150 mg | Sun Pharma Canada Inc. | 02406829 | AB57691 | May 2023 |
RAN- IRBESARTAN Tablets 150 mg | Sun Pharma Canada Inc. | 02406829 | AB57688 | May 2023 |
RAN- IRBESARTAN Tablets 150 mg | Sun Pharma Canada Inc. | 02406829 | AB57689 | May 2023 |
RAN- IRBESARTAN Tablets 150 mg | Sun Pharma Canada Inc. | 02406829 | AB58827 | May 2023 |
RAN- IRBESARTAN Tablets 150 mg | Sun Pharma Canada Inc. | 02406829 | 3990655 | November 2021 |
RAN- IRBESARTAN Tablets 300 mg | Sun Pharma Canada Inc. | 02406837 | AB47144 | April 2023 |
RAN- IRBESARTAN Tablets 300 mg | Sun Pharma Canada Inc. | 02406837 | AB47145 | April 2023 |
RAN- IRBESARTAN Tablets 300 mg | Sun Pharma Canada Inc. | 02406837 | AB58305 | May 2023 |
RAN- IRBESARTAN Tablets 300 mg | Sun Pharma Canada Inc. | 02406837 | AB58304 | May 2023 |
RAN- IRBESARTAN Tablets 300 mg | Sun Pharma Canada Inc. | 02406837 | AB58312 | May 2023 |
RAN- IRBESARTAN Tablets 300 mg | Sun Pharma Canada Inc. | 02406837 | AB58314 | May 2023 |
RAN- IRBESARTAN Tablets 300 mg | Sun Pharma Canada Inc. | 02406837 | AB58828 | May 2023 |
RAN- IRBESARTAN Tablets 300 mg | Sun Pharma Canada Inc. | 02406837 | AB57696 | May 2023 |
RAN- IRBESARTAN Tablets 300 mg | Sun Pharma Canada Inc. | 02406837 | AB70496 | June 2023 |
RAN- IRBESARTAN Tablets 300 mg | Sun Pharma Canada Inc. | 02406837 | AB70498 | June 2023 |
RAN- IRBESARTAN Tablets 300 mg | Sun Pharma Canada Inc. | 02406837 | AB70499 | June 2023 |
RAN- IRBESARTAN Tablets 300 mg | Sun Pharma Canada Inc. | 02406837 | 3991358 | November 2021 |
RAN- IRBESARTAN Tablets 300 mg | Sun Pharma Canada Inc. | 02406837 | 3991360 | November 2021 |
RAN- IRBESARTAN Tablets 75 mg | Sun Pharma Canada Inc. | 02406810 | AB47143 | April 2023 |
RAN- IRBESARTAN Tablets 75 mg | Sun Pharma Canada Inc. | 02406810 | AB58473 | May 2023 |
RAN- IRBESARTAN Tablets 75 mg | Sun Pharma Canada Inc. | 02406810 | AB58829 | May 2023 |
RAN- IRBESARTAN Tablets 75 mg | Sun Pharma Canada Inc. | 02406810 | 3994101 | November 2021 |
Sandoz IRBESARTAN 150 mg TABLETS | Sandoz Canada Inc. | 02328488 | KC7216 | July 2021 |
Sandoz IRBESARTAN 300 mg TABLETS | Sandoz Canada Inc. | 02328496 | KF8326 | July 2021 |
Sandoz IRBESARTAN HCT 150/12.5 mg TABLETS | Sandoz Canada Inc. | 02337428 | JF5840 | August 2021 |
Sandoz IRBESARTAN HCT 150/12.5 mg TABLETS | Sandoz Canada Inc. | 02337428 | JN4197 | January 2022 |
Sandoz IRBESARTAN HCT 150/12.5 mg TABLETS | Sandoz Canada Inc. | 02337428 | JN4971 | January 2022 |
Sandoz IRBESARTAN HCT 150/12.5 mg TABLETS | Sandoz Canada Inc. | 02337428 | JU3217 | January 2022 |
Sandoz IRBESARTAN HCT 150/12.5 mg TABLETS | Sandoz Canada Inc. | 02337428 | JV2167 | April 2022 |
Sandoz IRBESARTAN HCT 150/12.5 mg TABLETS | Sandoz Canada Inc. | 02337428 | JF8892 | August 2021 |
Sandoz IRBESARTAN HCT 150/12.5 mg TABLETS | Sandoz Canada Inc. | 02337428 | JN4191 | January 2022 |
Sandoz IRBESARTAN HCT 300/12.5 mg TABLETS | Sandoz Canada Inc. | 02337436 | JA4033 | February 2021 |
Sandoz IRBESARTAN HCT 300/12.5 mg TABLETS | Sandoz Canada Inc. | 02337436 | HY7383 | May 2021 |
Sandoz IRBESARTAN HCT 300/12.5 mg TABLETS | Sandoz Canada Inc. | 02337436 | JA4034 | May 2021 |
Sandoz IRBESARTAN HCT 300/12.5 mg TABLETS | Sandoz Canada Inc. | 02337436 | JE2529 | July 2021 |
Sandoz IRBESARTAN HCT 300/12.5 mg TABLETS | Sandoz Canada Inc. | 02337436 | JK7459 | October 2021 |
Sandoz IRBESARTAN HCT 300/12.5 mg TABLETS | Sandoz Canada Inc. | 02337436 | JK7460 | October 2021 |
Sandoz IRBESARTAN HCT 300/12.5 mg TABLETS | Sandoz Canada Inc. | 02337436 | JM3516 | October 2021 |
Sandoz IRBESARTAN HCT 300/12.5 mg TABLETS | Sandoz Canada Inc. | 02337436 | JM3517 | November 2021 |
Sandoz IRBESARTAN HCT 300/12.5 mg TABLETS | Sandoz Canada Inc. | 02337436 | JR7821 | February 2022 |
Sandoz IRBESARTAN HCT 300/12.5 mg TABLETS | Sandoz Canada Inc. | 02337436 | JU7500 | April 2022 |
Sandoz IRBESARTAN HCT 300/12.5 mg TABLETS | Sandoz Canada Inc. | 02337436 | JU7501 | April 2022 |
Sandoz IRBESARTAN HCT 300/12.5 mg TABLETS | Sandoz Canada Inc. | 02337436 | JU7502 | April 2022 |
Sandoz IRBESARTAN HCT 300/12.5 mg TABLETS | Sandoz Canada Inc. | 02337436 | JU7503 | April 2022 |
Sandoz IRBESARTAN HCT 300/12.5 mg TABLETS | Sandoz Canada Inc. | 02337436 | JY0147 | April 2022 |
Sandoz IRBESARTAN HCT 300/12.5 mg TABLETS | Sandoz Canada Inc. | 02337436 | JM4631 | November 2021 |
Sandoz IRBESARTAN HCT 300/12.5 mg TABLETS | Sandoz Canada Inc. | 02337436 | JZ2686 | April 2022 |
Sandoz IRBESARTAN HCT 300/25 mg TABLETS | Sandoz Canada Inc. | 02337444 | JB0221 | May 2021 |
Sandoz IRBESARTAN HCT 300/25 mg TABLETS | Sandoz Canada Inc. | 02337444 | JB0222 | May 2021 |
Sandoz IRBESARTAN HCT 300/25 mg TABLETS | Sandoz Canada Inc. | 02337444 | JC4402 | June 2021 |
Sandoz IRBESARTAN HCT 300/25 mg TABLETS | Sandoz Canada Inc. | 02337444 | JC4404 | June 2021 |
Sandoz IRBESARTAN HCT 300/25 mg TABLETS | Sandoz Canada Inc. | 02337444 | JH2487 | June 2021 |
Sandoz IRBESARTAN HCT 300/25 mg TABLETS | Sandoz Canada Inc. | 02337444 | JR7112 | January 2022 |
Sandoz IRBESARTAN HCT 300/25 mg TABLETS | Sandoz Canada Inc. | 02337444 | JR7833 | January 2022 |
Sandoz IRBESARTAN HCT 300/25 mg TABLETS | Sandoz Canada Inc. | 02337444 | JU3181 | February 2022 |
Sandoz IRBESARTAN HCT 300/25 mg TABLETS | Sandoz Canada Inc. | 02337444 | JW9512 | May 2022 |
Sandoz IRBESARTAN HCT 300/25 mg TABLETS | Sandoz Canada Inc. | 02337444 | JW9513 | May 2022 |
Sandoz IRBESARTAN HCT 300/25 mg TABLETS | Sandoz Canada Inc. | 02337444 | KC1750 | August 2022 |
Sandoz IRBESARTAN HCT 300/25 mg TABLETS | Sandoz Canada Inc. | 02337444 | JE1833 | June 2021 |
Sandoz IRBESARTAN HCT 300/25 mg TABLETS | Sandoz Canada Inc. | 02337444 | JR8726 | January 2022 |
Losartan | ||||
AURO-LOSARTAN 100 mg TABLETS | Auro Pharma Inc. | 02403358 | WB1019001-A | 14 August 2022 |
AURO-LOSARTAN 100 mg TABLETS | Auro Pharma Inc. | 02403358 | WB1019001-B | 14 August 2022 |
AURO-LOSARTAN 25 mg TABLETS | Auro Pharma Inc. | 02403323 | WB2519001-A | 14 August 2022 |
AURO-LOSARTAN 50 mg TABLETS | Auro Pharma Inc. | 02403331 | WB5019001-A | 14 August 2022 |
AURO-LOSARTAN 50 mg TABLETS | Auro Pharma Inc. | 02403331 | WB5019001-B | 14 August 2022 |
LOSARTAN /TABLET/100 mg | Sivem Pharmaceuticals ULC | 02388812 | 2151119 | November 2023 |
LOSARTAN /TABLET/25 mg | Sivem Pharmaceuticals ULC | 02388790 | 0080620 | June 2023 |
LOSARTAN /TABLET/25 mg | Sivem Pharmaceuticals ULC | 02388790 | 0090620 | June 2023 |
LOSARTAN/TABLET/100 mg | Sivem Pharmaceuticals ULC | 02388812 | 2101018 | October 2021 |
LOSARTAN/TABLET/100 mg | Sivem Pharmaceuticals ULC | 02388812 | 2020219 | February 2022 |
LOSARTAN/TABLET/100 mg | Sivem Pharmaceuticals ULC | 02388812 | 2030219 | February 2022 |
LOSARTAN/TABLET/100 mg | Sivem Pharmaceuticals ULC | 02388812 | 2040219 | February 2022 |
LOSARTAN/TABLET/100 mg | Sivem Pharmaceuticals ULC | 02388812 | 2090619 | June 2022 |
LOSARTAN/TABLET/100 mg | Sivem Pharmaceuticals ULC | 02388812 | 2100919 | September 2022 |
LOSARTAN/TABLET/100 mg | Sivem Pharmaceuticals ULC | 02388812 | 2110919 | September 2022 |
LOSARTAN/TABLET/100 mg | Sivem Pharmaceuticals ULC | 02388812 | 2120919 | September 2022 |
LOSARTAN/TABLET/100 mg | Sivem Pharmaceuticals ULC | 02388812 | 2130919 | September 2022 |
LOSARTAN/TABLET/100 mg | Sivem Pharmaceuticals ULC | 02388812 | 2050420 | April 2023 |
LOSARTAN/TABLET/100 mg | Sivem Pharmaceuticals ULC | 02388812 | 2060420 | April 2023 |
LOSARTAN/TABLET/100 mg | Sivem Pharmaceuticals ULC | 02388812 | 2070817 | August 2021 |
LOSARTAN/TABLET/100 mg | Sivem Pharmaceuticals ULC | 02388812 | 2040218 | February 2022 |
LOSARTAN/TABLET/100 mg | Sivem Pharmaceuticals ULC | 02388812 | 2140919 | September 2023 |
LOSARTAN/TABLET/25 mg | Sivem Pharmaceuticals ULC | 02388790 | 0050919 | September 2022 |
LOSARTAN/TABLET/25 mg | Sivem Pharmaceuticals ULC | 02388790 | 0060919 | September 2022 |
LOSARTAN/TABLET/25 mg | Sivem Pharmaceuticals ULC | 02388790 | 0070919 | September 2022 |
LOSARTAN/TABLET/25 mg | Sivem Pharmaceuticals ULC | 02388790 | 0080919 | September 2022 |
LOSARTAN/TABLET/25 mg | Sivem Pharmaceuticals ULC | 02388790 | 0080919A | September 2022 |
LOSARTAN/TABLET/25 mg | Sivem Pharmaceuticals ULC | 02388790 | 0101019 | October 2022 |
LOSARTAN/TABLET/25 mg | Sivem Pharmaceuticals ULC | 02388790 | 0101019A | October 2022 |
LOSARTAN/TABLET/25 mg | Sivem Pharmaceuticals ULC | 02388790 | 0030120 | January 2023 |
LOSARTAN/TABLET/25 mg | Sivem Pharmaceuticals ULC | 02388790 | 0040120 | January 2023 |
LOSARTAN/TABLET/50 mg | Sivem Pharmaceuticals ULC | 02388804 | 1121018 | October 2021 |
LOSARTAN/TABLET/50 mg | Sivem Pharmaceuticals ULC | 02388804 | 1131018 | October 2021 |
LOSARTAN/TABLET/50 mg | Sivem Pharmaceuticals ULC | 02388804 | 1130819 | August 2022 |
LOSARTAN/TABLET/50 mg | Sivem Pharmaceuticals ULC | 02388804 | 1140819 | August 2022 |
LOSARTAN/TABLET/50 mg | Sivem Pharmaceuticals ULC | 02388804 | 1150819 | August 2022 |
LOSARTAN/TABLET/50 mg | Sivem Pharmaceuticals ULC | 02388804 | 1160819 | August 2022 |
LOSARTAN/TABLET/50 mg | Sivem Pharmaceuticals ULC | 02388804 | 1180919 | September 2022 |
LOSARTAN/TABLET/50 mg | Sivem Pharmaceuticals ULC | 02388804 | 1070220 | February 2023 |
LOSARTAN/TABLET/50 mg | Sivem Pharmaceuticals ULC | 02388804 | 1080220 | February 2023 |
LOSARTAN/TABLET/50 mg | Sivem Pharmaceuticals ULC | 02388804 | 1090220 | February 2023 |
LOSARTAN/TABLET/50 mg | Sivem Pharmaceuticals ULC | 02388804 | 1100220 | February 2023 |
LOSARTAN/TABLET/50 mg | Sivem Pharmaceuticals ULC | 02388804 | 1110220 | February 2023 |
LOSARTAN/TABLET/50 mg | Sivem Pharmaceuticals ULC | 02388804 | 1060220 | February 2023 |
LOSARTAN/TABLET/50 mg | Sivem Pharmaceuticals ULC | 02388804 | 1170919 | September 2023 |
LOSARTAN/TABLET/50 mg | Sivem Pharmaceuticals ULC | 02388804 | 1120620 | June 2024 |
TEVA-LOSARTAN 100 mg TABLETS | Teva Canada Ltd. | 02357976 | 2010219 | February 2022 |
TEVA-LOSARTAN 100 mg TABLETS | Teva Canada Ltd. | 02357976 | 2010420 | April 2023 |
TEVA-LOSARTAN 100 mg TABLETS | Teva Canada Ltd. | 02357976 | 2020219 | February 2022 |
TEVA-LOSARTAN 100 mg TABLETS | Teva Canada Ltd. | 02357976 | 2020420 | April 2023 |
TEVA-LOSARTAN 100 mg TABLETS | Teva Canada Ltd. | 02357976 | 2030420 | April 2023 |
TEVA-LOSARTAN 100 mg TABLETS | Teva Canada Ltd. | 02357976 | 2040219 | February 2022 |
TEVA-LOSARTAN 100 mg TABLETS | Teva Canada Ltd. | 02357976 | 2060419 | April 2022 |
TEVA-LOSARTAN 100 mg TABLETS | Teva Canada Ltd. | 02357976 | 2080619 | June 2022 |
TEVA-LOSARTAN 100 mg TABLETS | Teva Canada Ltd. | 02357976 | 2080918 | September 2021 |
TEVA-LOSARTAN 100 mg TABLETS | Teva Canada Ltd. | 02357976 | 2091018 | October 2021 |
TEVA-LOSARTAN 100 mg TABLETS | Teva Canada Ltd. | 02357976 | 2101018 | October 2021 |
TEVA-LOSARTAN 100 mg TABLETS | Teva Canada Ltd. | 02357976 | 2161119 | November 2022 |
TEVA-LOSARTAN 100 mg TABLETS | Teva Canada Ltd. | 02357976 | 2171119 | November 2022 |
TEVA-LOSARTAN 100 mg TABLETS | Teva Canada Ltd. | 02357976 | 2030218 | February 2022 |
TEVA-LOSARTAN 100 mg TABLETS | Teva Canada Ltd. | 02357976 | 2070419 | April 2023 |
TEVA-LOSARTAN 100 mg TABLETS | Teva Canada Ltd. | 02357976 | 2181119 | November 2023 |
TEVA-LOSARTAN 100 mg TABLETS | Teva Canada Ltd. | 02357976 | 2191119 | November 2023 |
TEVA-LOSARTAN 100 mg TABLETS | Teva Canada Ltd. | 02357976 | 2140919 | September 2023 |
TEVA-LOSARTAN 25 mg TABLETS | Teva Canada Ltd. | 02380838 | 0010219 | February 2022 |
TEVA-LOSARTAN 25 mg TABLETS | Teva Canada Ltd. | 02380838 | 0020419 | April 2022 |
TEVA-LOSARTAN 25 mg TABLETS | Teva Canada Ltd. | 02380838 | 0030419 | April 2022 |
TEVA-LOSARTAN 25 mg TABLETS | Teva Canada Ltd. | 02380838 | 0031018 | October 2021 |
TEVA-LOSARTAN 25 mg TABLETS | Teva Canada Ltd. | 02380838 | 0040120 | January 2023 |
TEVA-LOSARTAN 25 mg TABLETS | Teva Canada Ltd. | 02380838 | 0040919 | September 2022 |
TEVA-LOSARTAN 25 mg TABLETS | Teva Canada Ltd. | 02380838 | 0050620 | June 2023 |
TEVA-LOSARTAN 25 mg TABLETS | Teva Canada Ltd. | 02380838 | 0050919 | September 2022 |
TEVA-LOSARTAN 25 mg TABLETS | Teva Canada Ltd. | 02380838 | 0060620 | June 2023 |
TEVA-LOSARTAN 25 mg TABLETS | Teva Canada Ltd. | 02380838 | 0070620 | June 2023 |
TEVA-LOSARTAN 25 mg TABLETS | Teva Canada Ltd. | 02380838 | 0010120 | January 2024 |
TEVA-LOSARTAN 25 mg TABLETS | Teva Canada Ltd. | 02380838 | 0020120 | January 2024 |
TEVA-LOSARTAN 50 mg TABLETS | Teva Canada Ltd. | 02357968 | 1040120 | January 2023 |
TEVA-LOSARTAN 50 mg TABLETS | Teva Canada Ltd. | 02357968 | 1030120 | January 2023 |
TEVA-LOSARTAN 50 mg TABLETS | Teva Canada Ltd. | 02357968 | 1040419 | April 2022 |
TEVA-LOSARTAN 50 mg TABLETS | Teva Canada Ltd. | 02357968 | 1050419 | April 2022 |
TEVA-LOSARTAN 50 mg TABLETS | Teva Canada Ltd. | 02357968 | 1060419 | April 2022 |
TEVA-LOSARTAN 50 mg TABLETS | Teva Canada Ltd. | 02357968 | 1070419 | April 2022 |
TEVA-LOSARTAN 50 mg TABLETS | Teva Canada Ltd. | 02357968 | 1080918 | September 2021 |
TEVA-LOSARTAN 50 mg TABLETS | Teva Canada Ltd. | 02357968 | 1090819 | August 2022 |
TEVA-LOSARTAN 50 mg TABLETS | Teva Canada Ltd. | 02357968 | 1090918 | September 2021 |
TEVA-LOSARTAN 50 mg TABLETS | Teva Canada Ltd. | 02357968 | 1100819 | August 2022 |
TEVA-LOSARTAN 50 mg TABLETS | Teva Canada Ltd. | 02357968 | 1101018 | October 2021 |
TEVA-LOSARTAN 50 mg TABLETS | Teva Canada Ltd. | 02357968 | 1110819 | August 2022 |
TEVA-LOSARTAN 50 mg TABLETS | Teva Canada Ltd. | 02357968 | 1111018 | October 2021 |
TEVA-LOSARTAN 50 mg TABLETS | Teva Canada Ltd. | 02357968 | 1121018 | October 2021 |
TEVA-LOSARTAN 50 mg TABLETS | Teva Canada Ltd. | 02357968 | 1130819 | August 2022 |
TEVA-LOSARTAN 50 mg TABLETS | Teva Canada Ltd. | 02357968 | 1180919 | September 2022 |
TEVA-LOSARTAN 50 mg TABLETS | Teva Canada Ltd. | 02357968 | 1010120 | January 2024 |
TEVA-LOSARTAN 50 mg TABLETS | Teva Canada Ltd. | 02357968 | 1030218 | February 2022 |
TEVA-LOSARTAN 50 mg TABLETS | Teva Canada Ltd. | 02357968 | 1080419 | April 2023 |
TEVA-LOSARTAN 50 mg TABLETS | Teva Canada Ltd. | 02357968 | 1120819 | August 2023 |
TEVA-LOSARTAN 50 mg TABLETS | Teva Canada Ltd. | 02357968 | 1141018 | October 2022 |
Valsartan | ||||
Sandoz Valsartan 160 mg TABLETS | Sandoz Canada Inc. | 02356767 | KT9598 | March 2023 |
Sandoz Valsartan 320 mg TABLETS | Sandoz Canada Inc. | 02356775 | KT8923 | April 2023 |
Sandoz Valsartan 320 mg TABLETS | Sandoz Canada Inc. | 02356775 | KV6185 | March 2023 |
Sandoz Valsartan 80 mg TABLETS | Sandoz Canada Inc. | 02356759 | KT7180 | March 2023 |
Sandoz Valsartan 80 mg TABLETS | Sandoz Canada Inc. | 02356759 | KT9515 | April 2023 |
VALSARTAN 160 mg TABLETS | Sanis Health Inc. | 02366967 | KT9597 | March 2023 |
SOURCE Health Canada
Der finanzen.at Ratgeber für Aktien!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.